Livesey Michael, Jauregui Julio J, Hamaker Max C, Pensy Raymond A, Langhammer Christopher G, Eglseder W Andrew
University of Maryland Medical Center, R Adams Cowley Shock Trauma Center, Department of Orthopaedic Surgery, USA.
J Orthop. 2020 Oct 16;22:497-502. doi: 10.1016/j.jor.2020.10.012. eCollection 2020 Nov-Dec.
We evaluated a cohort of patients who developed vasopressor-induced limb ischemia and the management options to prevent progression or minimize morbidity of digital necrosis.
We reviewed all current literature on pressor-induced limb ischemia and report options for the management of patients requiring vasopressors who developed limb ischemia. We then retrospectively reviewed presentation, treatment, and short-term outcomes for patients at our tertiary referral academic medical center that developed this complication. Finally, we recommend guidelines for the tiered management of these complex patients.
Thirty-six patients were included. Twenty-six patients (72%) required resuscitation with more than one vasopressor. Vasopressors were initiated for septic-shock (52.7%), cardiogenic-shock (16.7%), hypovolemic-shock (13.9%), acute transplant rejection (13.9%), and neurogenic-shock (2.8%). According to the tiered management recommendations, patients were managed with phase 1 care (19%), phase 2 care (8.3%), phase 3 care (50%) or phase 4 care (5.6%). The patient expired in the acute setting in 13.9% of cases.
Life-saving vasopressors risk digital ischemia and necrosis. Early recognition, reporting, and treatment of this complication are important in minimizing morbidity. Using a tiered approach helps organize the healthcare team's management of this iatrogenic complication while respecting the treatment paradigm of "life over limb," and may be safely performed with acceptable outcomes.
我们评估了一组发生血管升压药诱导肢体缺血的患者,以及预防病情进展或降低手指坏死发病率的管理方案。
我们回顾了目前所有关于升压药诱导肢体缺血的文献,并报告了对发生肢体缺血且需要血管升压药治疗的患者的管理方案。然后,我们回顾性分析了在我们三级转诊学术医疗中心发生该并发症的患者的临床表现、治疗及短期预后。最后,我们推荐了针对这些复杂患者的分层管理指南。
共纳入36例患者。26例患者(72%)需要使用一种以上血管升压药进行复苏。使用血管升压药的原因包括感染性休克(52.7%)、心源性休克(16.7%)、低血容量性休克(13.9%)、急性移植排斥反应(13.9%)和神经源性休克(2.8%)。根据分层管理建议,患者接受1期治疗(19%)、2期治疗(8.3%)、3期治疗(50%)或4期治疗(5.6%)。13.9%的患者在急性期死亡。
挽救生命的血管升压药有导致手指缺血和坏死的风险。早期识别、报告和治疗该并发症对于降低发病率很重要。采用分层方法有助于组织医疗团队对这种医源性并发症的管理,同时遵循“生命重于肢体”的治疗原则,并且可以安全实施并取得可接受的结果。